The metabolic divide is hardening into a permanent class structure. Following the expiry of semaglutide patents in India, over 50 generic brands have flooded the market, pricing the blockbuster weight-loss drug at a mere $15 a month for the Global South. In response, Novo Nordisk and the FDA have moved to protect the 'premium' market in the West. The recent approval of 'Wegovy HD'—a triple-dose variant—marks the creation of a tiered medical reality where effective treatment is reserved for those who can pay the corporate ransom.

This is the enclosure of biology. By securing FDA approval for high-dose versions and 'once-weekly' basal insulins like Awiqli, pharmaceutical giants are ensuring that their profit margins remain intact even as generic alternatives provide a lifeline to the poor. The medical industry is no longer focused on the eradication of disease, but on the management of health as a market commodity.

While billions of people in the Global South may finally access generic GLP-1 treatments, those in the United States remain trapped behind a paywall of insurance denials and high-cost patent extensions. The struggle for metabolic equity is the newest front in the class war, as the ruling class seeks to maintain its monopoly on the 'perfect' body while the rest of humanity is abandoned to a landscape of food deserts and pharmaceutical scarcity.